{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T04:48:08Z","timestamp":1768798088836,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chinese National Key Research and Development Program","award":["No. 2018YFC1707407"],"award-info":[{"award-number":["No. 2018YFC1707407"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common chronic digestive disease. Recent observational studies have reported that the Chinese herbal formula Huoxiang Zhengqi (HXZQ) can relieve IBS-D symptoms, but no high-level evidence is presented. Therefore, we want to evaluate the efficacy and safety of HXZQ for IBS-D patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a double-blind, randomized, placebo-controlled trial. The 212 eligible patients with IBS-D will be randomly assigned to receive either HXZQ oral liquid or a placebo, at a 1:1 ratio, for 4\u2009weeks with a 4-week follow-up period. Adequate relief will be the primary outcome measures. IBS symptom severity score, IBS quality-of-life questionnaire, EQ-5D-5L, and Chinese medicine symptom questionnaire will be the secondary outcome measures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This trial aims to demonstrate the efficacy and safety of HXZQ for IBS-D, which is expected to be an effective IBS-D treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The trial was registered with the Chinese Clinical Trial Registry, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=44613\">ChiCTR1900026837<\/jats:ext-link>. Registered on 24 October 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05444-w","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T21:02:42Z","timestamp":1627333362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Chinese herbal formula Huoxiang Zhengqi for diarrhea-predominant irritable bowel syndrome (CHAIRS): a study protocol for a double-blinded randomized controlled trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiaohui","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiling","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haomeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaogang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1797-2047","authenticated-orcid":false,"given":"Zehuai","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"5444_CR1","first-page":"615","volume-title":"Functional gastrointestinal disorders disorders of gut-brain interaction","author":"A Douglas","year":"2016","unstructured":"Douglas A, ROME D IV. Functional gastrointestinal disorders disorders of gut-brain interaction. Beijing: Science Press; 2016. p. 615\u20136."},{"key":"5444_CR2","first-page":"712","volume":"10","author":"RM Lovell","year":"2012","unstructured":"Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clinicalgastroenterology and hepatology. 2012;10:712\u201321.","journal-title":"Clinicalgastroenterology and hepatology"},{"issue":"6","key":"5444_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1365-2036.2005.02396.x","volume":"21","author":"JY Kang","year":"2005","unstructured":"Kang JY. Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;21(6):663\u201376. https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02396.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"5444_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5056\/jnm.2010.16.4.389","volume":"16","author":"FY Chang","year":"2010","unstructured":"Chang FY, Lu CL, Chen TS. The current prevalence of irritable bowel syndrome in Asia. Journal of neurogastroenterology and motility. 2010;16(4):389\u2013400. https:\/\/doi.org\/10.5056\/jnm.2010.16.4.389.","journal-title":"Journal of neurogastroenterology and motility"},{"key":"5444_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.5056\/jnm.2011.17.1.82","volume":"17","author":"GK Makharia","year":"2011","unstructured":"Makharia GK, Verma AK, Amarchand R, Goswami A, Singh P, Agnihotri A, et al. Prevalence of irritable bowel syndrome: a community based study from Northern India. Journal of Neurogastroenterology and Motility. 2011;17:82\u20137. https:\/\/doi.org\/10.5056\/jnm.2011.17.1.82.","journal-title":"Journal of Neurogastroenterology and Motility"},{"issue":"7","key":"5444_CR6","doi-asserted-by":"publisher","first-page":"A350","DOI":"10.1016\/j.jval.2015.09.634","volume":"18","author":"A Soubieres","year":"2015","unstructured":"Soubieres A, Pimentel M, Purdy C, Magar R. Inclusion of a novel IBS blood panel for diagnosing diarrhea predominant irritable bowel syndrome (IBS-D): a UK perspective. Value Health. 2015;18(7):A350. https:\/\/doi.org\/10.1016\/j.jval.2015.09.634.","journal-title":"Value Health"},{"issue":"16","key":"5444_CR7","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s40265-014-0292-7","volume":"74","author":"JL Barboza","year":"2014","unstructured":"Barboza JL, Talley NJ, Moshiree B. Current and emerging pharmacotherapeutic options for irritable bowel syndrome. Drugs. 2014;74(16):1849\u201370. https:\/\/doi.org\/10.1007\/s40265-014-0292-7.","journal-title":"Drugs"},{"key":"5444_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756284819878950","volume":"12","author":"DJ Cangemi","year":"2019","unstructured":"Cangemi DJ, Lacy BE. Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions. Ther Adv Gastroenterol. 2019;12:1\u201319.","journal-title":"Ther Adv Gastroenterol"},{"issue":"18","key":"5444_CR9","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/jama.280.18.1585","volume":"280","author":"A Bensoussan","year":"1998","unstructured":"Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA. 1998;280(18):1585\u20139. https:\/\/doi.org\/10.1001\/jama.280.18.1585.","journal-title":"JAMA"},{"issue":"3","key":"5444_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1142\/S0192415X15500251","volume":"43","author":"CY Li","year":"2015","unstructured":"Li CY, Tahir NAM, Li SC. A Systematic Review of Integrated Traditional Chinese and Western Medicine for Managing Irritable Bowel Syndrome. Am J Chin Med. 2015;43(3):385\u2013406. https:\/\/doi.org\/10.1142\/S0192415X15500251.","journal-title":"Am J Chin Med"},{"issue":"8","key":"5444_CR11","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.19540\/j.cnki.cjcmm.2017.0047","volume":"42","author":"HJ Zhao","year":"2017","unstructured":"Zhao HJ, Guo LP, Yang FW, Zhang MY, Zhang LS, Liu Z, et al. Huoxiang Zhengqi formulas for treatment of gastrointestinal type cold: a systematic review and Meta-analysis. Zhongguo Zhong Yao Za Zhi. 2017;42(8):1495\u20139. https:\/\/doi.org\/10.19540\/j.cnki.cjcmm.2017.0047.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"5444_CR12","first-page":"82","volume":"15","author":"W Lu","year":"2008","unstructured":"Lu W, Wu WJ. Progress in pharmacological research of Huoxiang Zhengqi prescription. Chinese Journal of Information on TCM. 2008;15:82\u20133.","journal-title":"Chinese Journal of Information on TCM"},{"issue":"4","key":"5444_CR13","first-page":"726","volume":"29","author":"ZX Fang","year":"2013","unstructured":"Fang ZX. Pharmacology and clinical study on the prevention and treatment of digestive tract diseases by formula of Huoxiang Zhengqi. Journal of Changchun University of Traditional Chinese Medicine. 2013;29(4):726\u20138.","journal-title":"Journal of Changchun University of Traditional Chinese Medicine"},{"issue":"3","key":"5444_CR14","first-page":"31","volume":"43","author":"GH Qiu","year":"2011","unstructured":"Qiu GH, Tang RD. Clinical Study of Jiawei Huoxiang Zhengqi Powder Combined with Western Medicine for Treatment of Diarrhea-predominant Irritable Bowel Syndrome. Journal of New Chinese Medicine. 2011;43(3):31\u20133.","journal-title":"Journal of New Chinese Medicine"},{"issue":"5","key":"5444_CR15","first-page":"376","volume":"15","author":"FK Cao","year":"2003","unstructured":"Cao FK, Qian J, Jin XJ, Yang Q, Liu WL, Xie XF, et al. Observation on treatment of 58 cases of diarrhea-type irritable bowel syndrome with Huoxiang Zhengqi powder plus prescription. Clinical Journal of Anhui Traditional Chinese Medicne. 2003;15(5):376\u20137.","journal-title":"Clinical Journal of Anhui Traditional Chinese Medicne"},{"issue":"3","key":"5444_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"key":"5444_CR17","unstructured":"State Administration of Traditional Chinese Medicine. Standards for diagnosis and curative effect of Chinese medical symptom. Nanjing: Nanjing University Publishing House; 1994. p. 9."},{"key":"5444_CR18","volume-title":"Diagnostics of Chinese Medicine [M]","author":"TT Deng","year":"2006","unstructured":"Deng TT. Diagnostics of Chinese Medicine [M], vol. 95. Shanghai: Shanghai Science and Technology Press; 2006."},{"issue":"7","key":"5444_CR19","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1111\/j.1572-0241.2006.00576.x","volume":"101","author":"WK Leung","year":"2006","unstructured":"Leung WK, Wu JC, Liang SM, Chan LS, Chan KL, Xie H, et al. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial. Am J Gastroenterol. 2006;101(7):1574\u201380. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00576.x.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"5444_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/030006059802600203","volume":"26","author":"AW Mangel","year":"1998","unstructured":"Mangel AW, Hahn BA, Heath AT, Northcutt AR, Kong S, Dukes GE, et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res. 1998;26(2):76\u201381. https:\/\/doi.org\/10.1177\/030006059802600203.","journal-title":"J Int Med Res"},{"issue":"6","key":"5444_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1046\/j.1365-2036.2003.01709.x","volume":"18","author":"E Corazziari","year":"2003","unstructured":"Corazziari E, Bytzer P, Delvaux M, Holtmann G, Malagelada JR, Morris J, et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2003;18(6):569\u201380. https:\/\/doi.org\/10.1046\/j.1365-2036.2003.01709.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"5444_CR22","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3109\/00365521.2013.825314","volume":"48","author":"LM Begtrup","year":"2013","unstructured":"Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarb\u00f8l DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome - a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol. 2013;48(10):1127\u201335. https:\/\/doi.org\/10.3109\/00365521.2013.825314.","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"5444_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","volume":"11","author":"CY Francis","year":"1997","unstructured":"Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395\u2013402. https:\/\/doi.org\/10.1046\/j.1365-2036.1997.142318000.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"5444_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1023\/A:1018831127942","volume":"43","author":"DL Patrick","year":"1998","unstructured":"Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998;43(2):400\u201311. https:\/\/doi.org\/10.1023\/A:1018831127942.","journal-title":"Dig Dis Sci"},{"key":"5444_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"5444_CR26","unstructured":"WHO. The use of the WHO-UMC system for standardised case causality assessment. 2018. https:\/\/www.who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf. Accessed Jan 2020."},{"issue":"10","key":"5444_CR27","first-page":"1191","volume":"36","author":"LQ Bian","year":"2016","unstructured":"Bian LQ, Lu F, Li ZH, Li BS, Gao R, Wang FY, et al. Analysis of Response of IBS-SSS, AR, and IBS-QOL in IBS Clinical Effect Evaluation. Chinese Journal of Integrated Traditional and Western Medicine. 2016;36(10):1191\u20136.","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine"},{"key":"5444_CR28","unstructured":"European Medicines Agency. Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. 2003. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/points-consider-evaluation-medicinal-products-treatment-irritable-bowel-syndromeen.pdf. Accessed Jan 2020."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05444-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05444-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05444-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T21:05:12Z","timestamp":1627333512000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05444-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5444"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05444-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"5 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for this trial protocol has been obtained from the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (number: BF2019-089-01). Results will be disseminated via peer-reviewed publications and presentations at conferences. Informed consent will be obtained from all participants. During screening, enrolling, and withdrawing from the trial, all personal patient information will be kept strictly confidential within the scope of the law, except for the inspection or monitoring of the source data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"491"}}